TME Pharma Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Aram Mangasarian

Chief Executive Officer (CEO)

€673.3k

Compensación total

Porcentaje del salario del CEO	37.1%
Permanencia del CEO	9.3yrs
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	3.7yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Aram Mangasarian en comparación con los beneficios de TME Pharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Jun 30 2024	n/a	n/a	-€6m
Mar 31 2024	n/a	n/a	-€7m
Dec 31 2023	€673k	€250k	-€7m
Sep 30 2023	n/a	n/a	-€8m
Jun 30 2023	n/a	n/a	-€8m
Mar 31 2023	n/a	n/a	-€12m
Dec 31 2022	€690k	€250k	-€15m
Sep 30 2022	n/a	n/a	-€17m
Jun 30 2022	n/a	n/a	-€18m
Mar 31 2022	n/a	n/a	-€16m
Dec 31 2021	€710k	€250k	-€14m
Sep 30 2021	n/a	n/a	-€13m
Jun 30 2021	n/a	n/a	-€11m
Mar 31 2021	n/a	n/a	-€11m
Dec 31 2020	€539k	€250k	-€10m
Sep 30 2020	n/a	n/a	-€8m
Jun 30 2020	n/a	n/a	-€5m
Mar 31 2020	n/a	n/a	-€3m
Dec 31 2019	€383k	€250k	-€861k
Sep 30 2019	n/a	n/a	-€5m
Jun 30 2019	n/a	n/a	-€9m
Mar 31 2019	n/a	n/a	-€10m
Dec 31 2018	€561k	€250k	-€11m
Sep 30 2018	n/a	n/a	-€9m
Jun 30 2018	n/a	n/a	-€7m
Mar 31 2018	n/a	n/a	-€6m
Dec 31 2017	€597k	€258k	-€5m

Compensación vs. Mercado: La compensación total de Aram($USD746.32K) está por encima de la media de empresas de tamaño similar en el mercado German ($USD535.71K).

Compensación vs. Ingresos: La compensación de Aram ha sido consistente con los resultados de la empresa en el último año.

CEO

Aram Mangasarian (54 yo)

9.3yrs

Permanencia

€673,251

Compensación

Dr. Aram Mangasarian, M.B.A., Ph D., has been the Chief Executive Officer and Member of Executive Board at TME Pharma N.V. (formerly known as NOXXON Pharma N.V.) (formerly known as NOXXON Pharma AG) since...

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Maurizio PetitBon	Independent Chairman of the Supervisory Board	8.8yrs	sin datos	sin datos
Daniel Von Hoff	Member of Scientific Advisory Board	3.7yrs	sin datos	sin datos
Lee Schalop	Member of the Supervisory Board	less than a year	sin datos	sin datos
Alexandra Glucksmann	Member of Supervisory Board	less than a year	sin datos	sin datos
Cornelis Izeboud	Independent Member of Supervisory Board	4.3yrs	€43.70k	sin datos
Susan Coles	Independent Deputy Chair of Supervisory Board	3.3yrs	€43.60k	sin datos
Jose Saro	Chairman of Scientific Advisory Board	3.7yrs	sin datos	sin datos
Gabriela Chiorean	Member of Scientific Advisory Board	3.7yrs	sin datos	sin datos
Eileen O'Reilly	Member of Scientific Advisory Board	3.7yrs	sin datos	sin datos
Thomas T. Seufferlein	Member of Scientific Advisory Board	3.7yrs	sin datos	sin datos
Michael Lim	Member of Scientific Advisory Board	2.4yrs	sin datos	sin datos
Monika Hegi	Member of Scientific Advisory Board	2.4yrs	sin datos	sin datos

3.7yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: La junta directiva de 0N6A se considera experimentada (3.5 años de antigüedad promedio).

TME Pharma Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

TME Pharma N.V. Announces Appointment of Alexandra Glucksmann to Supervisory Board

TME Pharma N.V. Appoints Lee Schalop as Member of the Supervisory Board

TME Pharma N.V., Annual General Meeting, Jun 29, 2023

TME Pharma N.V. Announces Executive Changes

NOXXON Pharma N.V. Announces Resignation of Gregory Weaver from its Supervisory Board, Effective September 30, 2022

NOXXON Pharma N.V., Annual General Meeting, Jun 29, 2022

Recent updates

TME Pharma N.V. Provides Clinical Update

TME Pharma N.V. Announces Appointment of Alexandra Glucksmann to Supervisory Board

TME Pharma N.V. Appoints Lee Schalop as Member of the Supervisory Board

New major risk - Negative shareholders equity

TME Pharma N.V. Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer

TME Pharma N.V. Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer

TME Pharma N.V. Announces FDA Clearance of Investigational New Drug (Ind) Application for Nox-A12 Phase 2 Trial in Brain Cancer

TME Pharma N.V. announced that it expects to receive €1.479999 million in funding

TME Pharma Announces Successful Advice Meeting with US Food and Drug Administration on Nox-A12 Development in Brain Cancer

TME Pharma N.V. announced that it has received €2.7 million in funding

New major risk - Financial position

TME Pharma N.V. Provides Positive Update on 18-Month Survival for NOX-A12 Combination Regimen in Brain Cancer

TME Pharma Announces Selection of Two Clinical Abstracts on the Ongoing NOX-A12 GLORIA Phase 1/2 Trial in Glioblastoma for Presentation at ESMO 2023 Congress and SNO 2023 Annual Meeting

Tme Pharma N.V. Announces NOX-A12 Combination Regimen with Bevacizumab: 17-Month Survival Rate Exceeds All Relevant Competitor Treatments Against Most Severe Form of Adult Brain Cancer

TME Pharma N.V. Provides Positive Data Update on Best Response to Therapy with First Complete Response in Glioblastoma, Bringing 50% of Patients in Expansion Arm to Complete or Near- Complete Response

TME Pharma N.V. Announces Positive 15-Month Survival Data from Gloria Expansion Arm Evaluating NOX-A12 in Combination with Radiotherapy and Bevacizumab in Glioblastoma

TME Pharma N.V. Receives Investigational New Drug (IND) Approval for NOX-A12 From the US FDA

TME Pharma N.V., Annual General Meeting, Jun 29, 2023

TME Pharma N.V. Provides Positive Clinical Update and 14-Month Survival Data from Gloria Expansion Arm Evaluating Nox-A12 in Combination with Radiotherapy and Bevacizumab in Glioblastoma

Tme Pharma Provides Clinical Update on the Gloria Expansion Arm Testing Nox-A12 in Combination with Radiotherapy and Bevacizumab in Patients with Glioblastoma

TME Pharma N.V. Announces Executive Changes

TME Pharma Announces Positive Updated Interim Results from NOX-A12 GLORIA Phase 1/2 in Brain Cancer Presented at the Society for Neuro-oncology 2022 Annual Meeting

TME Pharma Announces Publication of Abstract Disclosing Positive Interim Results from Bevacizumab Expansion Arm of NOX-A12 Gloria Phase 1/2 Brain Cancer Clinical Trial

TME Pharma N.V. Announces Data Safety Monitoring Board Validated Safety Data from the Initial Four Weeks of Treatment of the First Patient Enrolled in the GLORIA Phase 1/2 Clinical Trial Expansion Arm with NOX A12

TME Pharma Announces Enrollment of First Patient in Pembrolizumab Expansion Arm of NOX-A12 GLORIA Phase 1/2 Brain Cancer Clinical Trial

NOXXON Pharma N.V. Announces Resignation of Gregory Weaver from its Supervisory Board, Effective September 30, 2022

NOXXON Announces Updated Development Strategy Following Strong Clinical Benefit Observed With NOX-A12 in Combination With Radiotherapy and Bevacizumab in Brain Cancer

NOXXON Pharma N.V., Annual General Meeting, Jun 29, 2022

NOXXON Announces Presentation of NOX-A12 Phase 1/2 Data in Glioblastoma at The 2022 ASCO Annual Meeting and Invitation to a Dedicated KOL Event

Noxxon Pharma N.V. Announces Scientific Advisory Board Appointments

Top-Line Results from NOXXON’S NOX-A12 Phase 1/2 GLORIA Trial in Brain Cancer to Be Presented during 2022 ASCO Annual Meeting

NOXXON Provides Progress Update on the Expansion Arms of the Phase 1/2 GLORIA Trial With NOX-A12 in Brain Cancer Patients

NOXXON Pharma N.V. announced that it expects to receive €17 million in funding from Atlas Special Opportunities LLC

NOXXON Pharma N.V. Announces Enrolment of First Patient in the Expansion of the NOX-A12 Phase 1/2 Trial in Brain Cancer

NOXXON Pharma N.V. Presents New Phase 1/2 Data On NOX-A12 & Radiotherapy Combination in Brain Cancer at the Society for Neuro-Oncology Annual Meeting 2021

NOXXON Pharma N.V Enrolls Last Brain Cancer Patient in Dose Escalation Portion of GLORIA Study and Confirms Phase 1/2 Read-Out

NOXXON Provides Update on NOX-A12 Clinical Programs

Member of Supervisory Board J. deBethizy has left the company

Independent Member of the Supervisory Board Bertram Köhler has left the company

NOXXON Pharma N.V. Announces Positive Results from the Second Cohort in its Phase 1/2 Study of Nox-A12

NOXXON Announces Positive Results From Second Cohort in Phase 1/2 NOX-A12 Brain Cancer Trial

Noxxon Pharma N.V. Announces Data Safety Monitoring Board Validates NOX-A12 Highest Dose in Phase 1/2 Brain Cancer Trial

Noxxon Pharma N.V. Announces That the Data Safety Monitoring Board Analyzed Safety Data from the Initial Four Weeks of Treatment of the First Patient Enrolled in the Third and Final Dose Cohort of the NOX-A12 Plus

NOXXON Enrolls First Patient in the High Dose Cohort of Trial Combining NOX-A12 With Radiotherapy in Newly Diagnosed Brain Cancer

NOXXON Appoints Leading Pancreatic Cancer Experts to Scientific Advisory Board

NOXXON Pharma N.V. Appoints Jose Saro as Chair of Scientific Advisory Board

New 90-day high: €0.65

NOXXON Pharma N.V. Announces Initiation of NOX-A12 Manufacturing for Future Clinical Studies

NOXXON Pharma N.V. Announces That Data Safety Monitoring Board Validates Further Nox-A12 Dose Escalation in Phase 1/2 Brain Cancer Study

NOXXON Pharma N.V. Announces Completion of 6-Month Therapy for Low-Dose Cohort in Phase 1/2 Brain Cancer Study of NOX-A12 Plus Radiotherapy

Noxxon Pharma N.V. Announces Three Additional Clinical Centers to Recruit Patients for Nox-A12 Brain Cancer Trial

New 90-day low: €0.41

Noxxon Announces Successful Completion of Patient Recruitment for Second Dose Cohort in Phase 1/2 Brain Cancer Study of Nox-A12 Plus Radiotherapy

NOXXON Pharma N.V. Presents Final Clinical Data from Phase 1/2 NOX-A12 / Keytruda® Combination Trial in Colorectal and Pancreatic Cancer at the ESMO Virtual Congress 2020

NOXXON Pharma N.V. announced that it has received €0.499999 million in funding